Momenta Pharmaceuticals, Inc.
News and overview for Momenta Pharmaceuticals, Inc.
Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz
News-Medical.Net | 14 days 10 hours 54 minutes ago
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.
Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE -Related Patents [Press Release]
Business Wire | 14 days 13 hours 11 minutes ago
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.
Momenta rises on upgrade ahead of Lovenox ruling
Washington Post, The | 5 days 48 minutes ago
NEW YORK -- Shares of Momenta Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying Momenta will soon receive marketing approval for its version of the anti-clotting drug Lovenox.
Wire Business News
Sacramento Bee (Calif.), The | 5 days 1 hour 29 minutes ago
NEW YORK -- Shares of Momenta Pharmaceuticals Inc. rose Thursday after an analyst upgraded the stock, saying Momenta will soon receive marketing approval for its version of the anti-clotting drug Lovenox.
Teva Comments on Mylan Paragraph IV Filing for COPAXONE ; Files Lawsuit against Generic Filer for Patent Infringement [Press Release]
Business Wire | 38 days 23 hours 1 minute ago
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXONE® (glatiramer acetate injection), filed by Mylan Pharmaceuticals Inc. Teva also announced that it has filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and Natco Pharma Ltd. for patent infringement in the U.S. District Court for the Southern District of New York.
Israel stocks ease; Teva sues Mylan over Copaxone - MarketWatch
MarketWatch | 37 days 5 hours 2 minutes ago
Late in the trading day, the Tel Aviv Stock Exchange's benchmark TA-25 Index eased 0.12% to 1040.42, while the TA-100 Index /quotes/comstock/!ta100 (XX:TA100 972.96, +0.18, +0.02%) lost 0.11% to 971.88.
Teva wants to expand Copaxone patent lawsuit
Boston Globe, The | 14 days 6 hours 54 minutes ago
NEW YORKTeva Pharmaceutical Industries Ltd. said Tuesday it plans to expand a suit against Momenta Pharmaceuticals Inc. and Sandoz Inc., which are hoping to market a generic version of Teva's multiple sclerosis drug Copaxone.
Breathing easier
Boston Globe, The | 14 hours 3 minutes ago
LogMeIn Inc., a Woburn software company that raised $106 million by going public less than five months ago, was back in the stock market last week to sell more shares.
Senators Probe Drug Firm's Hiring of Kroll
Wall Street Journal, The | 22 days 17 hours ago
The race between two drug makers to market a generic version of a blockbuster blood thinner has grown so intense that one company hired the international detective and security firm Kroll, prompting an inquiry by two key senators.
Senators Probe Hiring Of Kroll by Drug Firm
Wall Street Journal, The | 22 days 13 hours 50 minutes ago
The race between two drug makers to market a generic version of a blockbuster blood thinner has grown so intense that one company hired the international detective and security firm Kroll, prompting an inquiry by two key senators.
Marathon Oil, Time Warner, GameStop are big movers
Philadelphia Inquirer, The | 4 days 21 hours 12 minutes ago
NEW YORK - The following stocks were among those that moved substantially or traded heavily Thursday on the New York Stock Exchange:
US HOT STOCKS: Dell, Zumiez, SkillSoft Active In Late Trading
Wall Street Journal, The | 4 days 20 hours 45 minutes ago
U.S. stocks closed lower Thursday, as the Dow Jones Industrial Average lost 94 points to 10332, the S&P 500 fell 15 points to 1095 and the Nasdaq Composite Index dropped 36 points to 2157. Among the companies whose shares are trading after hours are Dell Inc. (DELL), Zumiez Inc. (ZUMZ) and SkillSoft PLC's (SKIL).
US HOT STOCKS: Hot Topic, Dick's Sporting, Jack In The Box
Wall Street Journal, The | 5 days 1 hour 20 minutes ago
U.S. stocks traded lower Thursday, as the Dow Jones Industrial Average lost 152 points to 10274, the S&P 500 fell 20 points to 1090 and the Nasdaq Composite Index dropped 46 points to 2147. Among the companies whose shares are actively trading are Hot Topic Inc. (HOTT), Dick's Sporting Goods Inc. (DKS) and Jack in the Box Inc. (JACK).
Marsha Fanucci Joins Ironwood Board of Directors [Press Release]
PRNewswire | 28 days 3 hours 12 minutes ago
...served at Millennium Pharmaceuticals, Inc. from 2000-2009...Arthur D. Little, Inc. "We are thrilled...board of directors of Momenta Pharmaceuticals, where she chairs...Ironwood Pharmaceuticals, Inc. CONTACT: Susan...
Teva files suit against Sandoz, Momenta over patent infringement
Drug Store News | 14 days 1 hour 58 minutes ago
By Alaric DeArmentJERUSALEM (Nov. 10) Teva Pharmaceutical Industries has motioned to amend a complaint against two generic drug makers over their alleged infringement of Teva s patent on a multiple sclerosis drug.
Sign up for AANP SmartBrief
Company Overview
| Company: | Momenta Pharmaceuticals, Inc. |
|---|---|
| Industry: | Biotechnology |
| Website: | http://www.momentapharma.com |
Momenta Pharmaceuticals looks to increase momentum for its drug candidates. The biotech company specializes in engineering complex sugars to improve versions of existing drugs, as well as to discover more-effective new drugs. By analyzing complex sugars, the company provides a more comprehensive picture of the roles sugars play in cell function, disease, and drug action. Momenta has several products in the pipeline, including M-Enoxaparin, a generic version of heparin drug Lovenox from Sanofi-Aventis to treat patients with deep-vein thrombosis and acute coronary syndromes. The company is also developing a generic version of multiple sclerosis treatment Copaxone (marketed by Sanofi-Aventis and Teva).
Key Numbers
| Sales in U.S. Dollars (mil.) | 14.6 (2008) |
|---|---|
| One-year % Growth in Sales | -32.4 (2008) |
| Net Income in U.S. Dollars (mil.) | -62.6 (2008) |
| One-year % Growth in Net Income | 0.0 (2008) |
| Number of Employees | 167 (2008) |
| One-year % Growth in Number of Employees | 2.5 (2008) |
| Fiscal Year-End | December |